Published in Int Immunopharmacol on February 11, 2011
Sunitinib in Sarcomas of the Central Nervous System | NCT03641326
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc (2014) 2.03
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer (2016) 1.39
Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer (2013) 1.31
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol (2014) 1.26
The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis (2012) 1.00
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.95
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res (2013) 0.93
A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res (2014) 0.92
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One (2014) 0.92
Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol (2013) 0.91
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer (2012) 0.88
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88
Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol (2015) 0.88
TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother (2012) 0.86
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem (2013) 0.86
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget (2015) 0.85
Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. PLoS One (2011) 0.85
Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med (2016) 0.84
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol (2016) 0.83
Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer. Mediators Inflamm (2015) 0.83
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Res (2016) 0.83
Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology (2016) 0.83
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. PLoS One (2015) 0.82
Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL (2014) 0.82
Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts. J Pharmacol Exp Ther (2012) 0.82
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol (2011) 0.82
Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease. Age (Dordr) (2014) 0.81
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res (2015) 0.80
Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med (2014) 0.80
Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. J Immunol (2016) 0.80
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology (2015) 0.79
On the origin of myeloid-derived suppressor cells. Oncotarget (2016) 0.78
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther (2012) 0.78
Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol (2015) 0.77
A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment. Oncol Rep (2016) 0.77
Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway. Cancer Microenviron (2014) 0.76
TALEN mediated targeted editing of GM2/GD2-synthase gene modulates anchorage independent growth by reducing anoikis resistance in mouse tumor cells. Sci Rep (2015) 0.76
The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood. Clin Exp Immunol (2016) 0.76
Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep (2016) 0.75
One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer Metastasis Rev (2016) 0.75
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. Hum Vaccin Immunother (2015) 0.75
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol (2016) 0.75
Macrophage Migration Inhibitory Factor Secretion Is Induced by Ionizing Radiation and Oxidative Stress in Cancer Cells. PLoS One (2016) 0.75
The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. Med Oncol (2017) 0.75
CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment. Sci Rep (2015) 0.75
Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. Oncoimmunology (2017) 0.75
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol (2017) 0.75
Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer. Oncotarget (2017) 0.75
HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape. Oncotarget (2017) 0.75
Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma. Cancer Sci (2017) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 3.00
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res (2007) 2.49
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun (2007) 2.36
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res (2007) 2.19
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res (2003) 2.00
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci (2009) 1.58
The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol (2005) 1.44
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res (2010) 1.34
Targeted therapy for metastatic renal cell carcinoma. Br J Cancer (2006) 1.29
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood (2008) 1.06
Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Int Immunopharmacol (2009) 0.87
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Racial/ethnic differences in surgical outcomes in veterans following knee or hip arthroplasty. Arthritis Rheum (2005) 1.72
The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem (2013) 1.22
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.13
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol (2005) 1.12
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther (2009) 1.07
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 1.05
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer (2012) 0.97
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res (2008) 0.96
Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother (2011) 0.95
Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res (2014) 0.95
Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res (2011) 0.94
Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer (2011) 0.94
Differential expression of caveolin-1 in renal neoplasms. Cancer (2007) 0.93
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med (2010) 0.91
The Bcl-2 transgene protects T cells from renal cell carcinoma-mediated apoptosis. Clin Cancer Res (2003) 0.89
Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol (2009) 0.87
Risk factors for severity and type of the hip fracture. J Bone Miner Res (2009) 0.87
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol (2011) 0.83
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs (2010) 0.83
Participation in high-impact sports predicts bone mineral density in senior olympic athletes. Sports Health (2009) 0.82
Renal cell carcinoma: ten years of significant advances. Target Oncol (2010) 0.81
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Invest New Drugs (2013) 0.80
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv (2011) 0.80
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs (2013) 0.79
Kidney cancer in 2012: new frontiers in kidney cancer research. Nat Rev Urol (2013) 0.78
Kidney cancer: Does hypothyroidism predict clinical outcome? Nat Rev Urol (2010) 0.77
Amisulpride and cardiomyopathy. Aust N Z J Psychiatry (2005) 0.76
Researchers should ensure that their actions are lawful. Nature (2006) 0.75
Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. Head Neck (2010) 0.75
Effect of exercise on heart-rate response to mental stress in teenagers. Eur J Prev Cardiol (2012) 0.75
Practice challenges affecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas. J Community Support Oncol (2014) 0.75
Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. Arch Otolaryngol Head Neck Surg (2008) 0.75
Mixed Versus Pure Variants of Desmoplastic Melanoma: The Cleveland Clinic Experience. Ann Plast Surg (2017) 0.75
Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications. J Immunother (2007) 0.75
The use of sunitinib in renal cell carcinoma: where are we now? Expert Rev Anticancer Ther (2014) 0.75